Kenvue Inc. (NYSE:KVUE - Get Free Report) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totalling 35,720,000 shares, a decline of 8.6% from the December 15th total of 39,060,000 shares. Based on an average trading volume of 13,550,000 shares, the short-interest ratio is presently 2.6 days. Currently, 1.9% of the company's stock are short sold.
A number of hedge funds have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company's stock worth $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. State Street Corp boosted its stake in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Kenvue by 8.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock worth $2,011,832,000 after buying an additional 7,115,374 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kenvue by 0.9% in the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock worth $1,029,810,000 after buying an additional 399,846 shares during the last quarter. Finally, Harris Associates L P boosted its position in Kenvue by 7.5% during the third quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock worth $727,658,000 after purchasing an additional 2,186,114 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Shares of KVUE stock opened at $21.11 on Friday. The stock's 50-day simple moving average is $22.42 and its 200-day simple moving average is $21.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market capitalization of $40.46 billion, a PE ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period in the prior year, the company earned $0.31 earnings per share. The company's revenue was down .4% on a year-over-year basis. Equities analysts expect that Kenvue will post 1.14 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.89%. Kenvue's payout ratio is 149.09%.
Several research firms have recently commented on KVUE. Royal Bank of Canada raised Kenvue from a "hold" rating to a "moderate buy" rating in a research report on Monday, December 9th. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday. Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and reduced their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $23.08.
Get Our Latest Stock Analysis on KVUE
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.